Clinical trials · Michigan
Post-essential Thrombocythemia Myelofibrosis clinical trials in Michigan
We’re tracking 5 recruiting post-essential thrombocythemia myelofibrosis studies with a site in Michigan — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Michigan
- NCT05320198RecruitingPhase 1/Phase 2
Testing DISC-0974 for anemia in myelofibrosis or MDS
This trial tests an investigational drug called DISC-0974 for people with myelofibrosis or certain types of MDS who have low red blood cell counts (anemia). The goal is to see if this treatment can help improve anemia and reduce the need for blood transfusions.
Ann Arbor, MichiganAges 18 years+ - NCT07469891RecruitingPhase 1
Study of PRT12396 for JAK2-positive blood cancers
This trial tests an experimental drug, PRT12396, for people with certain blood cancers (polycythemia vera or myelofibrosis) that have a specific JAK2 mutation. It aims to see if the drug is safe and starts to work against the disease.
Grand Rapids, MichiganAges 18 years+ - NCT06343805RecruitingPhase 1
Study of AJ1-11095 for myelofibrosis after failed JAK2 inhibitor
This trial tests an experimental drug called AJ1-11095 for people with myelofibrosis who no longer respond to a type of JAK2 inhibitor. It aims to see if the drug can shrink the spleen, improve symptoms, and be safe.
Ann Arbor, MichiganAges 18 years+ - NCT06351631RecruitingPhase 3
Long-term safety study of bomedemstat for blood cancers
This trial checks the long-term safety and continued benefits of bomedemstat for people with certain blood cancers (like essential thrombocythemia and polycythemia vera) who have already been doing well on the drug in an earlier study.
Ann Arbor, MichiganAges 18 years+ - NCT06517875RecruitingPhase 2
Testing momelotinib plus luspatercept for transfusion-dependent myelofibrosis
This study tests a combination of two drugs, momelotinib and luspatercept, for people with myelofibrosis who need regular red blood cell transfusions. The goal is to see if the combination can reduce transfusion needs and improve symptoms.
Ann Arbor, MichiganAges 18 years+
Post-essential Thrombocythemia Myelofibrosis trials by city in Michigan
Where these studies are running in Michigan
Institutions with a site for the recruiting post-essential thrombocythemia myelofibrosis studies listed above.
- University of Michigan · 3 studies
- GSK Investigational Site
- START Midwest
What taking part in a post-essential thrombocythemia myelofibrosis study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Post-essential Thrombocythemia Myelofibrosis trials in other states
Common questions
- Are there post-essential thrombocythemia myelofibrosis clinical trials in Michigan?
- Yes. We're currently tracking 5 recruiting post-essential thrombocythemia myelofibrosis studies with a site in Michigan, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a post-essential thrombocythemia myelofibrosis study in Michigan?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Michigan to take part?
- Not necessarily. These studies have a site in Michigan, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a post-essential thrombocythemia myelofibrosis trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New post-essential thrombocythemia myelofibrosis studies open in Michigan regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.